Tilray Medical wins EU testing approval while Tilray Brands stock costs EUR 2.59
Published on 10/22/2026 at 14:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSOperating figures and key dates
- Tilray Medical received Portugal testing approval on October 13, 2026.
- Fiscal first-quarter revenue rose 23.00 percent to USD 257.15 million.
- Tilray Brands stock trades at EUR 2.59 at 2:45 p.m. CEST at Lang & Schwarz on October 22, 2026, 0.77 percent below the Xetra close of October 21, 2026.
- Tilray's annual shareholder meeting is scheduled for November 18, 2026.
Tilray Brands stock (ISIN US88688T2096) costs EUR 2.59 at Lang & Schwarz on October 22, 2026, at 2:45 p.m. CEST, 0.77 percent below the Xetra close of October 21, 2026 at EUR 2.61. The latest company event was a Portugal regulatory approval that gives Tilray Medical in-house quality-testing capacity, according to Finanznachrichten on October 13, 2026.
Approval targets faster product release
INFARMED authorized Tilray Medical's Cantanhede facility to conduct microbiological and chemical and physical testing on-site. The approval could reduce reliance on outside testing and shorten batch-release timelines across regulated European markets, according to Finanznachrichten.
Three dated steps for Tilray
On September 22, 2026, Tilray said it had invested nearly GBP 50 million in BrewDog operations, working capital and personnel, according to Finanznachrichten. On October 7, 2026, BrewDog reported Punk IPA and Hazy Jane sales at 2.87 times the prior-year volume across six retailers, also reported by Finanznachrichten. On October 13, 2026, the Portugal testing approval became the latest dated step.
What does beverage growth mean?
Tilray's fiscal first-quarter results show why the beverage division is central to the investment case. Revenue for the three months ended August 31, 2026, rose 23.00 percent year over year to USD 257.15 million, while gross profit increased 35.00 percent to USD 77.51 million, according to Tilray Brands on October 8, 2026. Beverage revenue rose 82.00 percent to USD 101.50 million, but adjusted EBITDA declined to USD 9.21 million from USD 10.18 million.
Next date for shareholders
Tilray's next explicitly scheduled corporate date is its annual shareholder meeting on November 18, 2026, according to the company's investor-relations calendar at Tilray Brands. The calendar also identifies the October 8, 2026 first-quarter earnings call as completed.
Stock stays near its yearly low
For investors, the contrast is clear: fiscal first-quarter revenue expanded, while adjusted EBITDA fell 9.58 percent year over year and the stock trades close to its finance-data 52-week low of USD 2.91. The primary listing is Nasdaq, where the stock was last quoted at USD 2.92 on October 21, 2026 at 4:00 p.m. ET.
Tilray Brands stock was trading at EUR 2.59 at Lang & Schwarz on October 22, 2026 at 2:45 p.m. CEST, 0.77 percent below the Xetra close of October 21, 2026 at EUR 2.61. The further course of trading is shown by the continuously updated real-time quote of Tilray Brands stock.
Tilray Brands stock facts
- Company: Tilray Brands, Inc.
- ISIN: US88688T2096
- WKN: A41VMJ
- Ticker: TLRY
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 22, 2026, 2:45 p.m. CEST): EUR 2.59
- Change versus Xetra close: minus 0.77 percent
- Xetra close (October 21, 2026): EUR 2.61
- Market capitalization: USD 326.5 million (as of October 21, 2026)
- Sector / Industry: Consumer packaged goods, cannabis and beverage
Market context: Market report S&P 500.
